4.5 Review

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines

期刊

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ijnp/pyw109

关键词

bipolar disorder; anticonvulsants; antidepressants; antipsychotics; evidence; based guidelines; lithium; mania; bipolar depression; mood stabilizers; treatment; clinical trials

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. Eli Lilly
  4. Ferrer
  5. Gedeon Richter
  6. Janssen
  7. Lundbeck
  8. Otsuka
  9. Pfizer
  10. Pfizer Foundation
  11. Sanofi-Aventis
  12. Servier
  13. Shire
  14. Allergan
  15. Dainippon Sumitomo Pharma
  16. Forest Research Institute
  17. GlaxoSmithKline
  18. Lilly
  19. Roche
  20. Sunovion
  21. Takeda
  22. Brain and Behaviour Foundation
  23. Spanish Ministry of Science and Innovation (CIBERSAM)
  24. Seventh European Framework Programme (ENBREC)
  25. Stanley Medical Research Institute
  26. NIHR-BRC (UK)
  27. NIMH (USA)
  28. CIHR (Canada)
  29. NARSAD (USA)
  30. Stanley Medical Research Institute (USA)
  31. MRC (UK)
  32. Wellcome Trust (UK)
  33. Royal College of Physicians (Edin)
  34. BMA (UK)
  35. UBC-VGH Foundation (Canada)
  36. WEDC (Canada)
  37. CCS Depression Research Fund (Canada)
  38. MSFHR (Canada)
  39. NIHR (UK)
  40. NIHR UK
  41. MRC UK
  42. NTW NHS Foundation Trust
  43. Gedeon-Richter
  44. Hofmann-LaRoche
  45. BMS
  46. Janssen-Cilag
  47. Alkermes
  48. Bristol Myers Squibb
  49. CANMAT
  50. CIHR
  51. Forest
  52. Intas
  53. Michael Smith Foundation for Health Research
  54. Sumitomo Dainippon
  55. Stanley Foundation
  56. Angelini
  57. AOP Orphan Pharmaceuticals AG
  58. KRKA-Pharma
  59. Neuraxpharm
  60. Pierre Fabre
  61. Schwabe
  62. Bayer
  63. Canadian Institute for Health Research
  64. Ontario Brain Institute
  65. Meda-Valeant
  66. Merck
  67. Pierre Fabre Medicaments

向作者/读者索取更多资源

Background: The current paper introduces the actual International College of Neuro-Psychopharmacology clinical guidelines for the treatment of bipolar disorder. Concept and structure of the guidelines: The current clinical guidelines are based on evidence-based data, but they also intend to be clinically useful, while a rigid algorithm was developed on the basis of firm evidence alone. Monotherapy was prioritized over combination therapy. There are separate recommendations for each of the major phases of bipolar disorder expressed as a 5-step algorithm. Discussion: The current International College of Neuro-Psychopharmacology clinical guidelines for the treatment of bipolar disorder are the most up-to-date guidance and are as evidence based as possible. They also include recommendations concerning the use of psychotherapeutic interventions, again on the basis of available evidence. This adherence of the workgroup to the evidence in a clinically oriented way helped to clarify the role of specific antidepressants and traditional agents like lithium, valproate, or carbamazepine. The additional focus on specific clinical characteristics, including predominant polarity, mixed features, and rapid cycling, is also a novel approach. Many issues need further studies, data are sparse and insufficient, and many questions remain unanswered. The most important and still unmet need is to merge all the guidelines that concern different phases of the illness into a single one and in this way consider BD as a single unified disorder, which is the real world fact. However, to date the research data do not permit such a unified approach.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据